[A21-38] Remdesivir (COVID-19) - Benefit assessment according to §35a Social Code Book V
Last updated 01.07.2021
Project no.:
A21-38
Commission:
Commission awarded on 01.04.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
COVID-19 in adults and adolescents (aged 12 years and older with body weight at least 40 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)
Adult patients with low-flow oxygen (LFO) at start of treatment: indication of considerable benefit.
Adolescent patients with low-flow oxygen (LFO) at start of treatment: added benefit not proven.
Patients with high-flow oxygen (HFO)/non-invasive ventilation (NIV) at start of treatment: added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A22-112 | Remdesivir (COVID-19, without supplemental oxygen, < 18 years of age) – Benefit assessment according to § 35a Social Code Book V | Commission completed |
| A22-113 | Remdesivir (COVID-19, requirement for additional oxygen supply, = 4 weeks - < 12 years of age) – Benefit assessment according to § 35a Social Code Book V | Commission completed |
| A22-04 | Remdesivir (COVID-19) - Benefit assessment according to §35a Social Code Book V | Commission completed |